[{"id":"58702155-c7f5-4adb-9515-8aecf200fa86","acronym":"","url":"https://clinicaltrials.gov/study/NCT04620681","created_at":"2021-01-19T20:34:25.590Z","updated_at":"2024-07-02T16:35:20.265Z","phase":"Phase 1/2","brief_title":"CD8 Depleted, Non-engrafting, HLA Mismatched Unrelated Infusion With MDS and Secondary AML","source_id_and_acronym":"NCT04620681","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" JAK2 • RUNX1 • SF3B1 • ASXL1 • TET2 • SRSF2 • BCOR • U2AF1 • STAG2 • CALR • CDKN1A • ZRSR2","pipe":" | ","alterations":" TP53 mutation • Chr del(11q) • U2AF1 mutation • Chr del(5q) • Chr del(7q)","tags":["JAK2 • RUNX1 • SF3B1 • ASXL1 • TET2 • SRSF2 • BCOR • U2AF1 • STAG2 • CALR • CDKN1A • ZRSR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • Chr del(11q) • U2AF1 mutation • Chr del(5q) • Chr del(7q)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 19","initiation":"Initiation: 01/14/2021","start_date":" 01/14/2021","primary_txt":" Primary completion: 08/10/2024","primary_completion_date":" 08/10/2024","study_txt":" Completion: 08/10/2024","study_completion_date":" 08/10/2024","last_update_posted":"2024-02-08"},{"id":"0d3ee8f5-d80e-4d1b-9490-6b52ff00aad7","acronym":"","url":"https://clinicaltrials.gov/study/NCT00816413","created_at":"2021-07-05T16:06:13.151Z","updated_at":"2024-07-02T16:35:40.198Z","phase":"Phase 1/2","brief_title":"Donor Stem Cell Transplant, Pentostatin, and Total-Body Irradiation in Treating Patients With Hematological Cancer","source_id_and_acronym":"NCT00816413","lead_sponsor":"University of Nebraska","biomarkers":" HLA-B • HLA-C","pipe":" | ","alterations":" Chr del(5q) • Chr del(7q)","tags":["HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr del(5q) • Chr del(7q)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclosporin A microemulsion • pentostatin • cyclosporine • ondansetron intravenous"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 09/01/2008","start_date":" 09/01/2008","primary_txt":" Primary completion: 02/01/2010","primary_completion_date":" 02/01/2010","study_txt":" Completion: 02/01/2010","study_completion_date":" 02/01/2010","last_update_posted":"2023-08-14"},{"id":"f69db2be-05a6-45ef-a79d-7dae6afc1775","acronym":"","url":"https://clinicaltrials.gov/study/NCT01760655","created_at":"2021-01-18T07:44:19.143Z","updated_at":"2024-07-02T16:35:58.053Z","phase":"Phase 2","brief_title":"Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies","source_id_and_acronym":"NCT01760655","lead_sponsor":"Sidney Kimmel Cancer Center at Thomas Jefferson University","biomarkers":" TP53 • FLT3","pipe":" | ","alterations":" TP53 deletion • Chr del(5q) • Chr del(7q)","tags":["TP53 • FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 deletion • Chr del(5q) • Chr del(7q)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • thiotepa • busulfan • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 62","initiation":"Initiation: 12/24/2012","start_date":" 12/24/2012","primary_txt":" Primary completion: 04/15/2022","primary_completion_date":" 04/15/2022","study_txt":" Completion: 12/05/2022","study_completion_date":" 12/05/2022","last_update_posted":"2023-01-06"},{"id":"7d0269ef-d62a-464e-b888-7fb2fa28d120","acronym":"","url":"https://clinicaltrials.gov/study/NCT05250362","created_at":"2022-02-22T13:52:32.086Z","updated_at":"2024-07-02T16:36:15.354Z","phase":"Phase 1/2","brief_title":"Ex Vivo Expanded NK Cells Infusion Decrease Relapse Post Hematopoietic Stem Cell Transplantation","source_id_and_acronym":"NCT05250362","lead_sponsor":"Sichuan University","biomarkers":" FLT3 • DNMT3A • TET2","pipe":" | ","alterations":" FLT3 mutation • DNMT3A mutation • Chr del(7q)","tags":["FLT3 • DNMT3A • TET2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation • DNMT3A mutation • Chr del(7q)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • cyclophosphamide"],"overall_status":"Recruiting","enrollment":" Enrollment 56","initiation":"Initiation: 03/01/2022","start_date":" 03/01/2022","primary_txt":" Primary completion: 02/28/2025","primary_completion_date":" 02/28/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2022-03-15"},{"id":"837927b2-eb6b-4652-92eb-3c2283ccc219","acronym":"","url":"https://clinicaltrials.gov/study/NCT02487459","created_at":"2021-01-18T11:58:41.219Z","updated_at":"2024-07-02T16:36:40.421Z","phase":"Phase 1/2","brief_title":"Safety Study of Gene Modified Donor T-Cells in Adults With Advanced Hematologic Malignancies","source_id_and_acronym":"NCT02487459","lead_sponsor":"Bellicum Pharmaceuticals","biomarkers":" FLT3 • KMT2A • HLA-DRB1 • HLA-B","pipe":" | ","alterations":" FLT3 mutation • MLL rearrangement • Chr del(5q) • Chr del(7q)","tags":["FLT3 • KMT2A • HLA-DRB1 • HLA-B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation • MLL rearrangement • Chr del(5q) • Chr del(7q)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CaspaCIDe DLI (rimiducid activated rivogenlecleucel) • rimiducid (AP1903)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 07/01/2016","start_date":" 07/01/2016","primary_txt":" Primary completion: 06/01/2017","primary_completion_date":" 06/01/2017","study_txt":" Completion: 06/01/2017","study_completion_date":" 06/01/2017","last_update_posted":"2020-10-05"},{"id":"74794339-c95b-4f68-b9e4-6e7534b0237e","acronym":"","url":"https://clinicaltrials.gov/study/NCT01010217","created_at":"2021-01-18T03:57:19.800Z","updated_at":"2024-07-02T16:36:47.655Z","phase":"Phase 2","brief_title":"Mismatched Transplantation Using High-dose Post-transplant Cyclophosphamide","source_id_and_acronym":"NCT01010217","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" FLT3 • KMT2A","pipe":" | ","alterations":" FLT3 mutation • MLL rearrangement • Chr del(5q) • Chr del(7q)","tags":["FLT3 • KMT2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation • MLL rearrangement • Chr del(5q) • Chr del(7q)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cyclophosphamide • melphalan • fludarabine IV • mesna • thiotepa • Neupogen (filgrastim) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 176","initiation":"Initiation: 11/05/2009","start_date":" 11/05/2009","primary_txt":" Primary completion: 10/05/2017","primary_completion_date":" 10/05/2017","study_txt":" Completion: 10/05/2017","study_completion_date":" 10/05/2017","last_update_posted":"2020-03-25"}]